- Companies
- cbdMD
cbdMD Valuation Multiples
cbdMD is valued at $4M as of October 2026, a 0.2x revenue multiple. In the last 12 months, cbdMD revenue was $22M.
cbdMD Overview
About cbdMD
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Founded
2015
HQ
Employees
42
Website
Financials (LTM)
EV
$4M
Valuation Multiples
Start free trialcbdMD Financials
cbdMD reported last 12-month revenue of $22M.
In the same LTM period, cbdMD generated $13M in gross profit and had net loss of ($3M).
cbdMD P&L
In the most recent fiscal year, cbdMD reported revenue of $19M and EBITDA of ($279K).
cbdMD is unprofitable as of last fiscal year, with gross margin of 62%, EBITDA margin of (1%), and net margin of (11%).
Financial data powered by Morningstar, Inc.
cbdMD Stock Performance
cbdMD has current market cap of $4M, and enterprise value of $4M.
Market Cap Evolution
cbdMD's stock price is $0.36.
cbdMD has an EPS (earnings per share) of $-0.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $4M | 0.6% | - | - | - | $-0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialcbdMD Valuation Multiples
cbdMD trades at 0.2x EV/Revenue multiple, and (15.0x) EV/EBITDA.
cbdMD Financial Valuation Multiples
As of October 28, 2026, cbdMD has market cap of $4M and EV of $4M.
cbdMD has a P/E ratio of (1.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified cbdMD Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


cbdMD Margins & Growth Rates
cbdMD grew revenue by 14% and net profit by 63% in the last fiscal year.
In the most recent fiscal year, cbdMD reported gross margin of 62%, EBITDA margin of (1%), and net margin of (11%).
cbdMD Margins
cbdMD Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
cbdMD Operational KPIs
cbdMD's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
cbdMD Competitors
cbdMD competitors include Strainsforpains, Spartoo, Tritent Intl, Panacea Life Sciences, Webuy Global, CordovaCann, Good Purpose Investments, Pomdoctor, Naples Soap and Weed.
Most cbdMD public comparables operate across Cannabis, Consumer E-commerce, CannaTech and ViceTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | - | - | |||
| $137M | $468K | 0.1x | 0.1x | 20.0x | 87.4x | |||
| - | - | - | - | - | - | |||
| $2M | ($5M) | 2.1x | - | (1.0x) | - | |||
| $19M | ($3M) | 0.1x | - | (0.7x) | - | |||
| $10M | ($584K) | 0.7x | - | (12.0x) | - | |||
| $7M | ($1M) | 0.7x | - | (3.6x) | - | |||
| $60M | ($18M) | 1.1x | - | (3.7x) | - | |||
This data is available for Pro users. Sign up to see all cbdMD competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by cbdMD
cbdMD has acquired 6 companies to date.
Last acquisition by cbdMD was on September 2nd 2026. cbdMD acquired Twinlab (brands and operating assets unit) for $4M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by cbdMD
| Description | Twinlab (brands and operating assets unit) is the supplement business comprising the Twinlab, Reserveage, Metabolife and Alvita Tea brands and the related operating assets sold to cbdMD through an assignment for the benefit of creditors. Founded in 1968, Twinlab is one of the best-known names in legacy supplements and sports nutrition, with products across vitamins, minerals, active lifestyle, beauty and performance nutrition sold to about 50,000 retail outlets, including Vitamin Shoppe and GNC, and strongly on Amazon. Reserveage focuses on longevity, resveratrol and collagen products, Metabolife on weight management and Alvita on teas. The business sells through wholesale, retail and online channels, and Anthony Zolezzi leads it as chief executive. Its predecessor group sold assets to IdeaSphere in an earlier bankruptcy and had a heavy debt burden before the 2026 sale. Operations are based in the United States. | Bluebird Botanicals is a hemp and CBD product manufacturer emphasizing third-party lab testing for purity. Boulder, Colorado-headquartered since 2012, it sells oils, capsules, and topicals through 5,000 retail partners nationwide. The company sources organic hemp from U.S. farms, producing full-spectrum extracts with 1,000 mg CBD per bottle options. | cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers. | I’M1 is a Seoul-based men’s apparel brand that specializes in casual and smart-casual clothing lines including shirts, trousers, jackets, and accessories. The company distributes its products through physical retail stores across South Korea and an e-commerce site at im1men.com. Established to appeal to style-conscious men, it emphasizes durable fabrics and contemporary fits suited for urban professionals. | |
| HQ Country | |||||
| HQ City | - | Louisville, KY | Charlotte, NC | Seoul | |
| Deal Date | 2 Sep 2026 | 14 Jan 2026 | 20 Dec 2018 | 5 Feb 2017 | |
| Valuation | $4M | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all cbdMD acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout cbdMD
| When was cbdMD founded? | cbdMD was founded in 2015. |
| Where is cbdMD headquartered? | cbdMD is headquartered in United States. |
| How many employees does cbdMD have? | As of today, cbdMD has over 42 employees. |
| Is cbdMD publicly listed? | Yes, cbdMD is a public company listed on NYSE American. |
| What is the stock symbol of cbdMD? | cbdMD trades under YCBD ticker. |
| When did cbdMD go public? | cbdMD went public in 2017. |
| Who are competitors of cbdMD? | cbdMD main competitors include Strainsforpains, Spartoo, Tritent Intl, Panacea Life Sciences, Webuy Global, CordovaCann, Good Purpose Investments, Pomdoctor, Naples Soap, Weed. |
| What is the current market cap of cbdMD? | cbdMD's current market cap is $4M. |
| What is the current revenue of cbdMD? | cbdMD's last 12 months revenue is $22M. |
| What is the current revenue growth of cbdMD? | cbdMD revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of cbdMD? | Current revenue multiple of cbdMD is 0.2x. |
| Is cbdMD profitable? | No, cbdMD is not profitable. |
| What is the current net income of cbdMD? | cbdMD's last 12 months net income is ($3M). |
| How many companies cbdMD has acquired to date? | As of October 2026, cbdMD has acquired 6 companies. |
| What was the largest acquisition by cbdMD? | $4M acquisition of Twinlab (brands and operating assets unit) on 2nd September 2026 was the largest M&A cbdMD has done to date. |
| In how many companies cbdMD has invested to date? | cbdMD hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to cbdMD
Lists including cbdMD
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




